The healthcare sector is outperforming the broader market and tech sector in Q4, confirming a substantial capital shift into ...

Duquesne Family Office's ~$4.06B 13F portfolio remains concentrated, with the top five holdings—Natera, Insmed, Teva Pharma, ...

The US government has negotiated a 71% discount for Novo Nordisk’s (NVO, NOVO-B.CO) weight-loss drugs Ozempic and Wegovy for ...

Novo Nordisk is quietly coming out of the storm despite the prevailing pessimism, especially among retail investors. Click for my latest analysis of NVO stock.

Detailed price information for Eli Lilly and Company (LLY-N) from The Globe and Mail including charting and trades.

Tim Seymour, Seymour Asset Management CIO, said in a recent program on CNBC that markets remain worried about AI valuations ...

Shares of Lucid logged their best day in about a month on Wednesday after the EV maker’s CFO Taoufiq Boussaid expressed ...

Among the batch of banks with earnings releases due are three of Canada's largest institutions: the Royal Bank of Canada RY, ...

In April 2025, CMG Pharmaceutical, a subsidiary of CHA Biotech, secured FDA approval for Mezofy (formerly Depipzo), an oral ...

While Novo Nordisk and Pfizer intensify their plays, Lilly’s early lead in GLP-1 treatments has put it in a category all its ...

Eli Lilly stock reached a new 52-week high on Nov. 10, up 4.7% and extending a month-long rally of 16%, after the pharmaceutical giant announced two strategic deals, following the highly anticipated ...

Drugmaker Eli Lilly is rolling out a new model to make it easier for employers to provide access to its GLP-1 drugs for weight management. Lilly said in an announcement that the model is built on ...